Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL3834380 | 0.97 | — | — | |
| Pyrrolidine SCHEMBL27400792 | 0.94 | LMNA (0.47) | ALDH1A1LMNAPMP22ALOX15BLM | |
| Piperidine SCHEMBL27748310 | 0.88 | ALDH1A1 (0.60) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL7344752 | 0.88 | ALDH1A1 (0.60) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL3283269 | 0.88 | ALDH1A1 (0.60) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL10332243 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL27769626 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL29043025 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL192668 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAPMP22KDM4EKMT2A | |
| Piperidine SCHEMBL8761997 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAPMP22KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506961-B1 | Processes for resolving piperidyl acetamide stereoisomers | CELGENE CORP (US) | 2012-02-22 | — | — | EP | claimed |
| US-7459560-B2 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 2008-12-02 | — | — | US | claimed |
| US-20060142583-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | KHETANI VIKRAM | 2006-06-29 | — | — | US | claimed |
| US-6962997-B1 | Process and intermediates for resolving piperidyl acetamide steroisomers | CELGENE CORPORATION (US) | 2005-11-08 | — | — | US | claimed |
| EP-1506961-A2 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 2005-02-16 | — | — | EP | claimed |
| US-20050014790-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION | 2005-01-20 | — | — | US | claimed |
| EP-0983238-A4 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORP (US) | 2001-08-08 | — | — | EP | claimed |
| EP-0983238-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| US-5936091-A | Processes and intermediates for resolving piperidyl acetamide stereoisomers | CELGENE CORPORATION (US) | 1999-08-10 | — | — | US | claimed |
| WO-1998052921-A1 | PROCESSES AND INTERMEDIATES FOR RESOLVING PIPERIDYL ACETAMIDE STEREOISOMERS | CELGENE CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
| US-11197857-B2 | Combination therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20210106580-A1 | COMBINATION THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-15 | — | — | US | disclosed |
| EP-3801530-A1 | COMBINATION OF A TYPE II PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR AND AN ICOS BINDING PROTEIN TO TREAT CANCER | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-04-14 | — | — | EP | disclosed |
| CN-112469416-A | Combination of type II protein arginine methyltransferase inhibitors and ICOS binding proteins for the treatment of cancer | 葛兰素史克知识产权开发有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20190350931-A1 | COMBINATION THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-21 | — | — | US | disclosed |
| CN-1213044-C | Amine and amide derivatives as ligands of the neuropeptide YY5 receptor for the treatment of obesity and other diseases | ORTHO MCNEIL PHARM INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| CN-1382135-A | Amine and amide derivatives as ligands for neuropeptide YY5 receptor usefu in treatment of obesity and other disorders | ORTHO MCNEIL PHARM INC (US) | 2002-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197857-B2 | Combination therapy | PRMT1, PRMT6, PRMT5 | ALDH1A1 3230/4885LMNA 3543/4885PMP22 4423/4885 |
| US-20210106580-A1 | COMBINATION THERAPY | PRMT1, PRMT6, PRMT5 | ALDH1A1 3230/4885LMNA 3543/4885PMP22 4423/4885 |
| US-20190350931-A1 | COMBINATION THERAPY | PRMT1, PRMT6, PRMT3 | ALDH1A1 3876/4885LMNA 4785/4885PMP22 3747/4885 |
| US-20050014790-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | NAAA, DHPS, CTPS2 | ALDH1A1 321/4885LMNA 2492/4885PMP22 1519/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | ALDH1A1 1663/4885LMNA 4715/4885PMP22 3251/4885 |
| US-20060142583-A1 | Processes and intermediates for resolving piperidyl acetamide stereoisomers | NAAA, DHPS, CTPS2 | ALDH1A1 321/4885LMNA 2492/4885PMP22 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.